QP 17 - Hem 3: Radiating Precision: Tailoring Therapy for Lymphoma, Leukemia, and Myeloma

Presentations

• 05:15pm - 06:15pm PT

  Hem 3: Radiating Precision: Tailoring Therapy for Lymphoma, Leukemia, and Myeloma

  Speaker: Nima Nabavizadeh, MD - Oregon Health & Science University, Portland
• 05:15pm - 06:15pm PT

  Hem 3: Radiating Precision: Tailoring Therapy for Lymphoma, Leukemia, and Myeloma

  Speaker: Rachel Rabinovitch, MD, FASTRO - University of Colorado Cancer Center, Aurora
• 05:20pm - 05:25pm PT

  Multimodal Imaging of the Functional and Physiological Bone Marrow Microenvironment in AML: Toward Personalized Clinical Applications

  Speaker: Susanta Hui, PhD - City of Hope National Medical Center, Duarte
• 05:25pm - 05:30pm PT

  Response Rate and Local Control of Response-Adapted Very Low Dose Radiotherapy (RA-VLDRT) with 4 Gy for Indolent Non-Hodgkin Lymphoma

  Speaker: Nikhil Mankuzhy, MD - Memorial Sloan Kettering Cancer Center, Middletown Township
• 05:30pm - 05:35pm PT

  Optimizing Palliative Radiation Therapy for Primary Cutaneous B-Cell Lymphoma: Is Ultra-Low Dose (4 Gy) Enough?

  Speaker: Gabrielle Gard, BS - University of Texas Southwestern Medical Center, Dallas
• 05:35pm - 05:40pm PT

  Bridging Radiotherapy for Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

  Speaker: Kristin Daniels, BS - UC San Diego, La Jolla
• 05:40pm - 05:45pm PT

  A Multi-Model Machine Learning Framework Identifies Resistance-Associated Biomarkers in Axicabtagene Ciloleucel CAR T-Cell Therapy for Large B-Cell Lymphoma

  Speaker: Wei Wu, PhD - Stanford University, San Jose
• 05:45pm - 05:50pm PT

  Consensus Organ at Risk (OAR) Constraints for Radiotherapy (RT) for Hematologic Malignancies for NCTN Trials

  Speaker: Austin Sim, MD, JD - The Ohio State University Comprehensive Cancer Center, Columbus